NDAORALTABLETPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
PAXLOVID (COPACKAGED) (nirmatrelvir and ritonavir) by Pfizer is 2 (sars-cov-2) antiviral drug [see ]. Approved for mild-to-moderate coronavirus disease 2019 (covid-19) in adults, including hospitalization, death. First approved in 2023.
Drug data last refreshed Yesterday
Mechanism of Action
2 (SARS-CoV-2) antiviral drug [see ]. Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 M. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.
Worked on PAXLOVID (COPACKAGED) at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.